A5005987696- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-related skin toxicity
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Gastrointestinal disorders and treatments
- Thyroid Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Central Venous Catheters and Hemodialysis
Hospital Universitario Río Hortega
2012-2023
GEICAM – Spanish Breast Cancer Group
2023
Central University Hospital of Asturias
2004-2016
Instituto de Investigación Sanitaria del Principado de Asturias
2004-2011
Institut Català d'Oncologia
2011
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2009
Universitat de Barcelona
2009
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2009
Fundación Instituto Valenciano de Oncología
2009
Hospital de León
2006
To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point survival, duration responses, time to progression, occurrence brain metastases (BM), assess safety quality life patients with disseminated cutaneous melanoma.Patients received either intravenous 100 mg/m2 weekly for 3 weeks or DTIC 250 mg/m2/d 5 consecutive days every 4 (two cycles). Nonprogressive a maintenance treatment (fotemustine days).Two hundred twenty-nine were randomly assigned...
To assess the activity and toxicity of combination gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) a randomized, multicenter, phase II study using DTIC alone as control arm.Patients previously treated STS were randomly assigned to receive either fixed-dose rate (10 mg/m2/min) at 1800 mg/m2 followed by 500 every 2 weeks, or 1200 3 weeks. The primary end point was progression-free (PFR) months.From November 2005 September 2008, 113 included. PFR months...
Purpose To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense ifosfamide in first-line treatment of advanced soft tissue sarcoma. Patients Methods measurable sarcoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2, between ages 18 65 years, adequate bone marrow, liver, renal function were entered study. The stratifications were: ECOG PS (0 v 1), location metastases, potentially...
Most chemotherapy treatments induce DNA damage in the exposed patients. Using comet assay and peripheral blood mononuclear cells (PBMC), we have quantified this induced studied its relationship with GSTM1 GSTT1 polymorphisms, clinical parameters. For purpose, 29 Caucasian women, breast cancer patients under CMF or CEF adjuvant were included study. The parameters considered (i) therapies side effects, like haematological biochemical toxicities, (ii) prognostic predictive factors, hormonal...
Abstract BACKGROUND Combinations of high‐dose ifosfamide (IF; 10–12 g/m 2 ) plus doxorubicin (DX; 50–90 mg/m have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt improve therapeutic efficacy. Although these combination regimens appear yield higher response rates than do standard‐dose regimens, they also are associated significant hematologic toxicity, despite the administration hematopoietic growth factor support. As a potentially less toxic alternative,...
Abstract BACKGROUND In the current study, authors set out to determine dose‐limiting toxicity (DLT) and maximum tolerated dose (MTD) associated with a combination of gemcitabine dacarbazine (DTIC) in patients advanced soft tissue sarcoma (ASTS), obtain preliminary information on activity this combination, explore possible pharmacodynamic interactions between DTIC. METHODS Every 2 weeks, 22 refractory ASTS received fixed–dose rate (10 mg/m /min) at escalating doses, which ranged from 800 2160...
Introduction Pegylated liposomal doxorubicin (PLD) is currently the reference treatment for platinum-resistant ovarian cancer. The combination of PLD and gemcitabine administration at a fixed dose rate infusion (FDRI) seem to have additive activity in this disease setting. We launched phase Ib study with FDRI followed by recurrent cancer platinum-free interval less than 1 year, parallel pharmacokinetic pharmacogenetic studies. Methods starting was 1500 mg/m 2 , 10 per minute, every weeks...
10529 Background: Dacarbazine (D) and gemcitabine (G) are active as single agents in the treatment of patients (pts) with advanced soft tissue sarcoma (STS) resistant to standard chemotherapy. The purpose this study was assess if combination D G (Buesa et al. Cancer. 2004;101:2261) improved clinical outcome compared D. Methods: Pts STS progressing after doxorubicin ifosfamide, PS 0–2, no prior or D, measurable disease adequate organ function, were randomized receive 1,800 mg/m2 a fixed dose...
Immunotherapy improves the survival of patients with advanced melanoma, 40% whom become long-term responders. However, not all respond to immunotherapy. Further knowledge processes involved in response and resistance immunotherapy is still needed. In this study, clinical paraffin samples from fifty-two melanoma treated anti-PD-1 inhibitors were assessed via high-throughput proteomics RNA-seq. The obtained transcriptomics data analyzed using multi-omics network analyses based on probabilistic...
10072 Background: Doxorubicin remains the standard of care for STS. Its use has been limited due to bone marrow and cardiac toxicity, specially in elderly patients (pts). GP-Pharm (Sarcodoxome)(DX-GP) is a non-pegylated liposomal formulation containing lipochromane-6. Previous Phase I study suggested activity low toxicity (CTOS 2008) Methods: Multicenter multinational II prospective trial advanced or metastatic STS pts aged ≥64 yr, asses efficacy safety DX-GP first line setting. Eligibility:...
Because no consensus exists regarding recommendable dose levels for irinotecan, an intrapatient escalation phase I-II study was initiated in previously treated patients with colorectal cancer. Survival a secondary endpoint. Thirty-five consecutive progressive disease after 5-fluorouracilbased chemotherapy were enrolled to receive irinotecan starting from 250 mg/m2/3 weeks and rising currently used therapeutic doses. In total, 162 cycles administered. The median tolerable mg/m2. Twelve (34%)...
Background: Spain has been severely affected by the COVID-19 epidemic, with 195,944 persons infected and 20,453 deaths at time of writing. Older people respiratory or cardiac conditions are most risk. Objective: The aim was to compare symptoms in nursing home residents patients uncontrolled asthma, who considered vulnerable COVID-19. Methods: We studied 134 139 groups Demographic characteristics, clinical manifestations, outcomes, key laboratory results, radiological images were collected...